# Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06088004/  
OnCo record `nct06088004` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Suzhou Abogen Biosciences Co., Ltd., now recruiting.

## Summary

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06088004 by Suzhou Abogen Biosciences Co., Ltd., with 218 participants planned, started 2023-09-28 and due to reach its primary completion in 2026-12-30. Interventions recorded: ABO2011 Injection and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06088004
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics (PK/PD) and Preliminary Efficacy of ABO2011 Monotherapy or in Combination With Toripalimab in Patients With Advanced Solid Tumors
- Sponsor: Suzhou Abogen Biosciences Co., Ltd.
- Enrolled: 218

## Sources

- ClinicalTrials.gov NCT06088004: https://clinicaltrials.gov/study/NCT06088004

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06088004.json